Since different histone methyl-transferases have been targeted for therapeutic treatment against cancers, our discovery of an initial cell loss followed by over-proliferation in response to the knockdown of a key histone methyl-transferase raises concerns about the potential use of these enzyme inhibitors in cancer therapy (Morera et al., 2016). Here, PRDM9 is linked to cancer.